51 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study http://www.zacks.com/stock/news/542841/astrazeneca-mercks-lynparza-improves-pfs-in-frontline-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542841 Sep 30, 2019 - AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.
Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study http://www.zacks.com/stock/news/542861/glaxos-zejula-betters-pfs-in-first-line-ovarian-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542861 Sep 30, 2019 - Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.
Seattle Genetics Up on Positive Data From Bladder Cancer Study http://www.zacks.com/stock/news/544569/seattle-genetics-up-on-positive-data-from-bladder-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-544569 Oct 01, 2019 - Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/545810/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-545810 Oct 02, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck's Pediatric Filings for Dificid Get FDA's Priority Review http://www.zacks.com/stock/news/547611/mercks-pediatric-filings-for-dificid-get-fdas-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-547611 Oct 03, 2019 - The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Novo Nordisk Focuses on Pipeline Development Amid Competition http://www.zacks.com/stock/news/552953/novo-nordisk-focuses-on-pipeline-development-amid-competition?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-552953 Oct 07, 2019 - Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
Top Ranked Growth Stocks to Buy for October 10th http://www.zacks.com/commentary/557775/top-ranked-growth-stocks-to-buy-for-october-10th?cid=CS-ZC-FT-zacks_#1_rank_additions-557775 Oct 10, 2019 - Top Ranked Growth Stocks to Buy for October 10th
Why Merck (MRK) is Poised to Beat Earnings Estimates Again http://www.zacks.com/stock/news/563650/why-merck-mrk-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-563650 Oct 14, 2019 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Dividend-Paying Pharma Stocks to Buy Now https://www.fool.com/investing/2019/10/15/3-dividend-paying-pharma-stocks-to-buy-now.aspx?source=iedfolrf0000001 Oct 15, 2019 - These aren't the highest payouts in the industry, but they have the best chance to steadily climb.
J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View http://www.zacks.com/stock/news/565810/jj-jnj-beats-on-q3-earnings-as-sales-rise-ups-2019-view?cid=CS-ZC-FT-analyst_blog|earnings_article-565810 Oct 15, 2019 - J&J (JNJ) comes up with encouraging third-quarter 2019 results.

Pages: 123456

<<<Page 5